F8 and cancer: These T-helper cells activate B cells, leading to the production of high-affinity IgG antibodies that neutralize FVIII activity [10]. This immune activation may be exacerbated in patients with malignancies, as the tumor microenvironment often fosters systemic inflammation, immune dysregulation, and heightened antigen presentation [11]. In addition, surgical interventions and associated tissue damage can amplify immune responses through the release of pro-inflammatory cytokines and damage-associated molecular patterns, further increasing the likelihood of inhibitor development.